These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34666045)

  • 1. Mechanistic Models for USP2 Dissolution Apparatus, Including Fluid Hydrodynamics and Sedimentation.
    Pepin X; Goetschy M; Abrahmsén-Alami S
    J Pharm Sci; 2022 Jan; 111(1):185-196. PubMed ID: 34666045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Evaluation of Dissolution Performance in a USP 2 Setup and Alternative Stirrers and Vessel Designs: A Systematic Computational Investigation.
    Salehi N; Al-Gousous J; Hens B; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2024 May; 21(5):2406-2414. PubMed ID: 38639477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel.
    Salehi N; Al-Gousous J; Mudie DM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2020 Oct; 17(10):3870-3884. PubMed ID: 32886520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.
    Wang M; Heimbach T; Zhu W; Wu D; Reuter KG; Kesisoglou F
    AAPS J; 2024 Jun; 26(4):69. PubMed ID: 38862807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of sinkers on coning issues exhibited by tablets in USP2 dissolution apparatus.
    Terashima H; Ozeki T
    Int J Pharm; 2024 Jun; 659():124236. PubMed ID: 38768693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective.
    Kollipara S; Bhattiprolu AK; Boddu R; Ahmed T; Chachad S
    AAPS PharmSciTech; 2023 Feb; 24(2):59. PubMed ID: 36759492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimum rotation speed to prevent coning phenomena in compendium paddle dissolution apparatus.
    Higuchi M; Yoshihashi Y; Tarada K; Sugano K
    Eur J Pharm Sci; 2014 Dec; 65():74-8. PubMed ID: 25240320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring bulk volume, particle size and particle motion definitions to increase the predictive ability of in vitro dissolution simulations.
    Navas-Bachiller M; Persoons T; D'Arcy DM
    Eur J Pharm Sci; 2022 Jul; 174():106185. PubMed ID: 35398291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input.
    Pepin XJH; Sanderson NJ; Blanazs A; Grover S; Ingallinera TG; Mann JC
    Eur J Pharm Biopharm; 2019 Sep; 142():421-434. PubMed ID: 31306753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report.
    Pepin X; Arora S; Borges L; Cano-Vega M; Carducci T; Chatterjee P; Chen G; Cristofoletti R; Dallmann A; Delvadia P; Dressman J; Fotaki N; Gray E; Heimbach T; Holte Ø; Kijima S; Kotzagiorgis E; Lennernäs H; Lindahl A; Loebenberg R; Mackie C; Malamatari M; McAllister M; Mitra A; Moody R; Mudie D; Musuamba Tshinanu F; Polli JE; Rege B; Ren X; Rullo G; Scherholz M; Song I; Stillhart C; Suarez-Sharp S; Tannergren C; Tsakalozou E; Veerasingham S; Wagner C; Seo P
    Mol Pharm; 2024 Aug; 21(8):3697-3731. PubMed ID: 38946085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro-in vivo correlation.
    Golhar A; Pillai M; Dhakne P; Rajput N; Jadav T; Sengupta P
    Int J Pharm; 2023 Aug; 643():123267. PubMed ID: 37488057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space - Part I: Adults.
    Pepin XJH; Hammarberg M; Mattinson A; Moir A
    Pharm Res; 2023 Feb; 40(2):387-403. PubMed ID: 36002614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the Potential for Dissolution Simulation to Explore the Effects of Medium Viscosity on Particulate Dissolution.
    D'Arcy DM; Persoons T
    AAPS PharmSciTech; 2019 Jan; 20(2):47. PubMed ID: 30617668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
    Wu D; Sanghavi M; Kollipara S; Ahmed T; Saini AK; Heimbach T
    Pharm Res; 2023 Feb; 40(2):337-357. PubMed ID: 35840856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
    Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
    J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.
    Aishwarya R; Murthy A; Ahmed T; Chachad S
    J Pharm Sci; 2022 Jun; 111(6):1820-1832. PubMed ID: 35217007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
    Eckernäs E; Tannergren C
    Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.